-
CSCO 2024 | Dr. Jian Zhang & Dr. Nadia Harbeck: East-West Collaboration on New Advances in Breast Cancer Treatment
As antibody-drug conjugates (ADCs) and precision medicine continue to develop, breast cancer is entering a new era of treatment. At the 2024 CSCO Annual Conference, Dr. Jian Zhang from Fudan University Shanghai Cancer Center and Dr. Nadia Harbeck from LMU University Hospital, Munich,Germany engaged in a deep discussion about the latest developments in breast cancer…
-
2024 CACA丨 How to Balance Hepatic Adjuvant Therapy? Dr. Minshan Chen Shares Advances and Strategies in Liver Cancer Adjuvant Treatment
Hepatology Digest: Could you discuss the evolution and clinical value of interventional therapy in postoperative adjuvant treatment for liver cancer? Dr. Minshan Chen: Interventional therapy is one method for preventing…
-
Dr. Shuihua Lu: Expanding from Tuberculosis-Free Communities to Tuberculosis-Free Cities with the Power of Technology丨15th Tuberculosis Eastern Forum
01 Infectious Diseases Frontier: Congratulations on the successful conclusion of the 15th Tuberculosis Eastern Forum! Could you introduce the history of the forum and the highlights of this year’s event?…
-
ESMO China’s Voice | Dr. Xiaojia Wang: Ivonescimab Dual PD-1/VEGF Blockade Achieves 72.4% ORR as a First-Line Therapy, Setting a New Standard for TNBC
The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As one of the largest and most prestigious clinical oncology conferences in the world, it showcased numerous cutting-edge research findings, driving global advancements in oncology. In the field of breast cancer, Dr. Xiaojia Wang from Zhejiang…
-
ESMO 2024 | Breakthrough in Immunotherapy: NICHE-2 Study Achieves 100% Three-Year Disease-Free Survival, Exceeding Expectations!
At the 2024 European Society for Medical Oncology (ESMO) Congress, Dr. Myriam Chalabi from Amsterdam, Netherlands, unveiled the latest results from the NICHE-2 study, showing a groundbreaking three-year disease-free survival (DFS) rate of 100% in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer undergoing neoadjuvant immunotherapy. This large-scale study provides critical evidence supporting neoadjuvant…
-
Shitong Huan: Improving Health Systems and Innovating Diagnostic and Treatment Tools to Eliminate Tuberculosis丨15th Tuberculosis Eastern Forum
Ending the “White Plague”: The Gates Foundation’s Ongoing Efforts and Achievements The Bill & Melinda Gates Foundation (Gates Foundation), founded in 2000, focuses on improving global health and development, particularly…
-
Dr. Feng Wang: Current Status and Challenges of Hepatocellular Carcinoma (HCC) Conversion Therapy in the Era of Integrated Medicine
Hepatology Digest: What is the core significance of conversion therapy for HCC under the concept of integrated medicine? How has it changed the traditional treatment approach for liver cancer? Dr.…
-
ESMO 2024 | Dr. Yao Zhu’s Team Explores Neoadjuvant Treatment Strategies for Localized High-Risk Prostate Cancer
The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. The team led by Dr. Yao Zhu from Fudan University Shanghai Cancer Center presented their research on the neoadjuvant treatment of localized high-risk prostate cancer, featuring a combination of ARSi and PARPi, which was…
Connecting Medical Expertise through Media